Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology

Friday, June 18, 2010 Research News
Email Print This Page Comment
Font : A-A+

New Data from Five Clinical Studies Reinforce RDEA594's Robust Efficacy and Encouraging Safety Profile

PK/PD Study Interim Results

sUA Response - % of Patients

Treatment Groups

Allopurinol 300 mg

Alone

(n = 11)

RDEA594 400 mg

+ Allopurinol 300 mg

(n = 6)

RDEA594 600 mg

+ Allopurinol 300 mg

(n = 5)

< 6 mg/dL

27%

100%

100%

< 5 mg/dL

9%

67%

100%

< 4 mg/dL

0%

0%

60%



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook